Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site, 2021 Q3 to 2026 Q2
- $21.7B
- 77 holdings
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
AUM over time
Book
| SPY, SPDR S&P 500 ETF Trust | New | 5,500,000 | $617.85 | $3.4B | +5,500,000 | +$3.4B | |
| MSFT, Microsoft | Reduce −23.5% | 1,747,835 | $497.41 | $869M | −538,000 | +$11M | |
| NTRA, Natera | Add +6.0% | 4,821,809 | $168.94 | $815M | +274,000 | +$171M | |
| Hess | New | 5,805,000 | $138.54 | $804M | +5,805,000 | +$804M | |
| AON, Aon | Add +45.9% | 1,986,417 | $356.76 | $709M | +624,673 | +$330M | |
| EXEL, Exelixis | Reduce −28.8% | 16,035,500 | $44.08 | $707M | −6,498,000 | −$125M | |
| AMZN, Amazon | New | 3,034,600 | $219.39 | $666M | +3,034,600 | +$666M | |
| IQV, IQVIA | Add +12.9% | 3,851,351 | $157.59 | $607M | +439,500 | +$5.4M | |
| DIS, Disney | Reduce −11.3% | 4,874,268 | $124.01 | $604M | −621,955 | +$62M | |
| CRM, Salesforce | Add +7.2% | 2,109,110 | $272.69 | $575M | +142,000 | +$47M | |
| TMO, Thermo Fisher Scientific | Add +33.5% | 1,383,241 | $405.46 | $561M | +347,385 | +$45M | |
| LNTH, Lantheus | Add +11.6% | 6,722,227 | $81.86 | $550M | +699,000 | −$38M | |
| ARMK, Aramark | Reduce −20.6% | 12,899,701 | $41.87 | $540M | −3,342,295 | −$21M | |
| ADSK, Autodesk | Reduce −12.7% | 1,744,652 | $309.57 | $540M | −252,748 | +$17M | |
| RVMD, Revolution Medicines | Add +5.8% | 14,325,692 | $36.79 | $527M | +791,000 | +$48M | |
| UNH, UnitedHealth Group | Add +8.0% | 1,617,300 | $311.97 | $505M | +119,400 | −$280M | |
| TRU, Transunion | Reduce −0.2% | 5,404,575 | $88.00 | $476M | −8,631 | +$26M | |
| GBTC, iShares Bitcoin Trust ETF | Add +21.2% | 7,020,050 | $61.21 | $430M | +1,226,250 | +$158M | |
| BSX, Boston Scientific | Add +5.8% | 3,981,057 | $107.41 | $428M | +218,300 | +$48M | |
| INTU, Intuit | Reduce −36.1% | 536,658 | $787.63 | $423M | −303,600 | −$93M | |
| HIMS, Hims & Hers Health | Add +3.3% | 8,213,581 | $49.85 | $409M | +259,876 | +$174M | |
| NDAQ, Nasdaq | Reduce −8.4% | 4,083,743 | $89.42 | $365M | −376,545 | +$27M | |
| SCHW, Charles Schwab | Add +3.3% | 3,959,057 | $91.24 | $361M | +126,200 | +$61M | |
| ANSS, Ansys | New | 997,128 | $351.22 | $350M | +997,128 | +$350M | |
| PTGX, Protagonist Therapeutics | Add +1.1% | 6,172,006 | $55.27 | $341M | +65,000 | +$46M | |
| BBIO, Bridgebio | Add +37.8% | 7,900,000 | $43.18 | $341M | +2,169,000 | +$143M | |
| NYT, New York Times | Reduce −37.2% | 5,609,546 | $55.98 | $314M | −3,322,567 | −$129M | |
| GOOG, Alphabet | Add +5.8% | 1,761,840 | $177.39 | $313M | +95,800 | +$52M | |
| ADI, Analog Devices | Reduce −4.1% | 1,272,200 | $238.02 | $303M | −54,800 | +$35M | |
| CBRE, CBRE Group | Reduce −15.3% | 2,113,138 | $140.12 | $296M | −382,562 | −$30M | |
| WAB, Wabtec | Reduce −18.6% | 1,308,198 | $209.35 | $274M | −299,900 | −$18M | |
| MCK, McKesson | Reduce −43.1% | 314,600 | $732.78 | $231M | −237,900 | −$141M | |
| WWD, Woodward | Reduce −35.6% | 914,673 | $245.09 | $224M | −505,027 | −$35M | |
| AGIO, Agios Pharmaceuticals | Add +1.2% | 5,767,466 | $33.26 | $192M | +67,000 | +$25M | |
| Holding | Add +66.8% | 1,810,000 | $94.58 | $171M | +725,011 | +$102M | |
| Azek | New | 3,141,400 | $54.35 | $171M | +3,141,400 | +$171M | |
| BEAM, Beam Therapeutics | Add +0.9% | 10,013,111 | $17.01 | $170M | +85,000 | −$24M | |
| CRNX | Add +0.9% | 4,646,098 | $28.76 | $134M | +41,000 | −$21M | |
| V, Visa | Reduce −34.9% | 308,810 | $355.05 | $110M | −165,400 | −$57M | |
| Championx | New | 4,245,000 | $24.84 | $105M | +4,245,000 | +$105M | |
| GEHC, GE HealthCare | Add +146.2% | 1,322,000 | $74.07 | $98M | +785,000 | +$55M | |
| THC, Tenet Healthcare | New | 529,000 | $176.00 | $93M | +529,000 | +$93M | |
| EHC, Encompass Health | Add +14.4% | 708,000 | $122.63 | $87M | +89,000 | +$24M | |
| MA, Mastercard | Reduce −24.5% | 152,071 | $561.94 | $85M | −49,300 | −$25M | |
| CAH, Cardinal Health | Add +66.3% | 454,000 | $168.00 | $76M | +181,000 | +$39M | |
| EDU | Reduce −11.5% | 1,155,150 | $53.95 | $62M | −150,000 | −$79K | |
| BBNX, Beta Bionics | Add +26.2% | 4,203,920 | $14.56 | $61M | +871,700 | +$20M | |
| CNTA, Centessa Pharmaceuticals | Add +4.5% | 4,529,318 | $13.14 | $60M | +195,000 | −$2.8M | |
| LQDA, Liquidia | Add +6.2% | 4,238,762 | $12.46 | $53M | +247,806 | −$6.1M | |
| FLUT, Flutter Entertainment | Reduce −24.9% | 181,229 | $285.76 | $52M | −60,238 | −$1.7M | |
| TNGX, Tango Therapeutics | Add +98.6% | 9,157,000 | $5.12 | $47M | +4,546,070 | +$41M | |
| SGRY, Surgery Partners | New | 1,926,000 | $22.23 | $43M | +1,926,000 | +$43M | |
| Verve Therapeutics | Add +296.1% | 3,612,000 | $11.23 | $41M | +2,700,000 | +$36M | |
| JOYY | Add +1.0% | 787,906 | $50.91 | $40M | +7,906 | +$7.4M | |
| HQY, Healthequity | Reduce −24.2% | 319,800 | $104.76 | $34M | −102,000 | −$3.8M | |
| RARE | New | 898,000 | $36.36 | $33M | +898,000 | +$33M | |
| OSCR, Oscar Health | Add +13318.2% | 1,476,000 | $21.44 | $32M | +1,465,000 | +$32M | |
| WGS, Genedx | Add +7.8% | 326,677 | $92.31 | $30M | +23,677 | +$3.3M | |
| GRAL, Grail | New | 502,000 | $51.42 | $26M | +502,000 | +$26M | |
| WAY, Waystar | Reduce −69.7% | 613,000 | $40.87 | $25M | −1,407,000 | −$50M | |
| SDGR, Schrodinger | New | 1,106,000 | $20.12 | $22M | +1,106,000 | +$22M | |
| VNET, Vnet Group | Add +22.8% | 2,994,120 | $6.90 | $21M | +555,000 | +$659K | |
| ALKS, Alkermes | Reduce −50.2% | 691,663 | $28.61 | $20M | −698,137 | −$26M | |
| ABT, Abbott Laboratories | Reduce −59.2% | 136,000 | $136.01 | $18M | −197,000 | −$26M | |
| YMM, Full Truck Alliance | Reduce −78.9% | 1,550,598 | $11.81 | $18M | −5,806,609 | −$76M | |
| Mr Cooper Group | New | 122,500 | $149.21 | $18M | +122,500 | +$18M | |
| PARA, Paramount Global | New | 1,346,151 | $12.90 | $17M | +1,346,151 | +$17M | |
| TECX, Tectonic Therapeutic | Hold | 853,050 | $19.87 | $17M | — | — | |
| ENTA, Enanta Pharmaceuticals | Hold | 2,122,262 | $7.56 | $16M | — | — | |
| Savara | Hold | 6,835,000 | $2.28 | $16M | — | — | |
| Mara | Hold | 835,000 | $15.68 | $13M | — | — | |
| Latam Airlines Group | Reduce −43.4% | 318,092 | $40.64 | $13M | −243,918 | −$4.7M | |
| GMED, Globus Medical | Add +153.0% | 210,000 | $59.02 | $12M | +127,000 | +$6.3M | |
| NUVL, Nuvalent | Hold | 150,000 | $76.30 | $11M | — | — | |
| TYRA, Tyra Biosciences | Hold | 1,143,818 | $9.57 | $11M | — | — | |
| CDTX, Cidara Therapeutics | New | 200,000 | $48.71 | $9.7M | +200,000 | +$9.7M | |
| Helix Acquisition Corporation II | Hold | 600,000 | $10.65 | $6.4M | — | — | |
| VYGR, Voyager Therapeutics | Reduce −72.2% | 715,000 | $3.11 | $2.2M | −1,855,700 | −$6.5M | |
| PRME, Prime Medicine | Hold | 750,000 | $2.47 | $1.9M | — | — | |
| ALVO, Alvotech | Hold | 199,675 | $9.12 | $1.8M | — | — | |
| SMC, Summit Midstream | Hold | 58,214 | $24.53 | $1.4M | — | — | |
| Janux Therapeutics | Hold | 48,000 | $23.10 | $1.1M | — | — | |
| MDGL, Madrigal Pharmaceuticals | Hold | 3,319 | $302.64 | $1M | — | — | |
| BTSG, Brightspring Health Services | Hold | 22,000 | $23.59 | $519K | — | — | |
| SLNO, Soleno Therapeutics | Hold | 5,000 | $83.78 | $419K | — | — | |
| AXSM, Axsome Therapeutics | Hold | 4,000 | $104.39 | $418K | — | — | |
| ROIV, Roivant Sciences | Hold | 37,000 | $11.27 | $417K | — | — | |
| CAPR | Reduce −98.2% | 41,000 | $9.93 | $407K | −2,209,400 | −$21M | |
| PGNY, Progyny | Hold | 18,000 | $22.00 | $396K | — | — | |
| Sage Therapeutics | Hold | 42,800 | $9.12 | $390K | — | — | |
| ARQT, Arcutis Biotherapeutics | Hold | 26,000 | $14.02 | $365K | — | — | |
| INSM, Insmed | Hold | 3,000 | $100.64 | $302K | — | — | |
| COR, Cencora | Hold | 1,000 | $299.85 | $300K | — | — | |
| UTHR, United Therapeutics | Hold | 1,000 | $287.35 | $287K | — | — | |
| TWST, Twist Bioscience | Hold | 7,650 | $36.79 | $281K | — | — | |
| MMSI, Merit Medical Systems | Hold | 3,000 | $93.48 | $280K | — | — | |
| KRYS, Krystal Biotech | Hold | 2,000 | $137.46 | $275K | — | — | |
| LIVN, Livanova | Reduce −83.8% | 6,000 | $45.02 | $270K | −31,000 | −$1.2M | |
| GKOS, Glaukos | Hold | 2,600 | $103.29 | $269K | — | — | |
| ONC, Beone Medicines | Hold | 1,100 | $242.07 | $266K | — | — | |
| ACLX, Arcellx | Hold | 4,000 | $65.85 | $263K | — | — | |
| SBRA, Sabra Health Care REIT | Hold | 14,000 | $18.44 | $258K | — | — | |
| GRFS, Grifols | Hold | 28,000 | $9.04 | $253K | — | — | |
| ARWR, Arrowhead Pharmaceuticals | Hold | 15,800 | $15.80 | $250K | — | — | |
| SRRK, Scholar Rock | Hold | 7,000 | $35.42 | $248K | — | — | |
| ASND, Ascendis Pharma A/s | Hold | 1,400 | $172.60 | $242K | — | — | |
| Springworks Therapeutics | Reduce −95.8% | 5,000 | $46.99 | $235K | −113,000 | −$5M | |
| BRKR, Bruker | Hold | 5,000 | $41.20 | $206K | — | — | |
| QURE, Uniqure | Hold | 14,000 | $13.94 | $195K | — | — | |
| IMVT, Immunovant | Hold | 12,000 | $16.00 | $192K | — | — | |
| HR, Healthcare Realty Trust | Hold | 12,000 | $15.86 | $190K | — | — | |
| PACB | Hold | 135,000 | $1.24 | $167K | — | — | |
| EVH, Evolent Health | Hold | 14,000 | $11.26 | $158K | — | — | |
| COGT, Cogent Biosciences | Hold | 17,000 | $7.18 | $122K | — | — | |
| ALT, Altimmune | Hold | 27,600 | $3.87 | $107K | — | — | |
| NVAX, Novavax | Hold | 16,000 | $6.30 | $101K | — | — | |
| DYN, Dyne Therapeutics | Hold | 10,000 | $9.52 | $95K | — | — | |
| SNDX, Syndax Pharmaceuticals | Hold | 10,000 | $9.36 | $94K | — | — | |
| FOLD, Amicus | Hold | 16,000 | $5.73 | $92K | — | — | |
| ARDX, Ardelyx | Hold | 23,000 | $3.92 | $90K | — | — | |
| GERN, Geron | Hold | 43,000 | $1.41 | $61K | — | — | |
| ANNA, Aleanna | Hold | 78,400 | $0.6347 | $50K | — | — | |
| IOVA, Iovance Biotherapeutics | Hold | 26,000 | $1.72 | $45K | — | — | |
| CCCC, C4 Therapeutics | Hold | 28,000 | $1.43 | $40K | — | — | |
| CGC, Canopy Growth | Hold | 30,000 | $1.22 | $37K | — | — | |
| Biodesix | Reduce −93.1% | 128,000 | $0.2822 | $36K | −1,731,308 | −$1.1M | |
| IRWD, Ironwood Pharmaceuticals | Hold | 13,000 | $0.7172 | $9K | — | — |
Showing top 50 of 127 by value
Exits / last held
Gone since 2025 Q1, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Intra-Cellular Therapies | Exit | 0 | $131.92 | $403M | −3,055,000 | −$403M | |
| Sarepta Therapeutics | Exit | 0 | $63.82 | $149M | −2,341,424 | −$149M | |
| BHVN, Biohaven | Exit | 0 | $24.04 | $116M | −4,813,167 | −$116M | |
| SGI, Somnigroup International | Exit | 0 | $59.88 | $79M | −1,326,242 | −$79M | |
| Zymeworks | Exit | 0 | $11.91 | $4.8M | −400,000 | −$4.8M | |
| Rxsight | Exit | 0 | $25.25 | $4.4M | −175,000 | −$4.4M | |
| Marblegate Acquisition | Exit | 0 | $11.05 | $1.7M | −150,000 | −$1.7M | |
| SIMO, Silicon Motion Technology | Exit | 0 | $50.55 | $1.5M | −29,298 | −$1.5M | |
| Cara Therapeutics | Exit | 0 | $5.07 | $658K | −129,685 | −$658K | |
| Forte Biosciences | Exit | 0 | $7.77 | $547K | −70,429 | −$547K | |
| Blueprint Medicines | Exit | 0 | $88.50 | $354K | −4,000 | −$354K | |
| CHE, Chemed | Exit | 0 | $615.00 | $246K | −400 | −$246K | |
| TMDX, Transmedics Group | Exit | 0 | $67.33 | $202K | −3,000 | −$202K | |
| ELAN, Elanco Animal Health | Exit | 0 | $10.50 | $168K | −16,000 | −$168K | |
| Beyond Meat | Exit | 0 | $3.05 | $58K | −19,000 | −$58K |
Filings history
20 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
Farallon Capital Management, L.l.c.
87 processed 13Fs on this site, 2021 Q3 to 2026 Q2